Ryan Dietz
Corporate Officer/Principal at Florida State University
Profile
Ryan Dietz is a partner in TIO Bioventures, bringing more than 20 years of experience in technology evaluation, intellectual property generation, licensing and partnering transactions, and company formation efforts to the firm.
Ryan also serves as Vice President, Corporate Development of TIO Bioventures’ flagship portfolio company Treadwell Therapeutics.
Prior to joining TIO, Ryan was a licensing executive with Boston Children’s Hospital, where he oversaw the hospital’s two largest research programs across all stages of development.
During his industry career, Ryan led technology development and intellectual property generation efforts for various prominent start-up biotechnology and pharmaceutical companies including Moderna, Scholar Rock, Magenta Therapeutics, and Morphic Therapeutic.
Each of these companies successfully completed IPOs in 2018 or 2019, including the largest IPO in biotechnology history with Moderna raising $620M at a $7.5B valuation.
Ryan also has extensive business development and alliance management experience and is an inventor and developer of multiple consumer products for musicians.
He holds a Bachelor of Arts degree in psychology and criminal justice from Indiana University Bloomington, and a JD in intellectual property and licensing from Suffolk University Law School.
Ryan Dietz active positions
Companies | Position | Start |
---|---|---|
Florida State University | Corporate Officer/Principal | - |
Tio Bioventures
Tio Bioventures Investment ManagersFinance Tio Bioventures (Tio Bioventures) is a venture capital firm founded in 2019 by Tak Wah Mak and Shane Burgess. The firm is headquartered in New York. | Private Equity Investor | 2019-12-31 |
Treadwell Therapeutics, Inc.
Treadwell Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Treadwell Therapeutics, Inc. operates as a clinical-stage oncology firm. It develops small molecules designed to leverage world-class, innovative science in cancer biology and immune-oncology with pan-cancer potential, including hematological malignancies from the TIO Discovery development engine. The company was founded by Tak Wah Mak and Mark R. Bray in July 2019 and is headquartered in New York, NY. | Corporate Officer/Principal | 2019-12-31 |
Former positions of Ryan Dietz
Companies | Position | End |
---|---|---|
Immune Disease Institute, Inc.
Immune Disease Institute, Inc. Immune Disease Institute, Inc. provides biomedical research services. It engages in doing fundamental research to improve human health, harness inflammation, and strengthen immune defense. The company was founded on January 19, 1953 and is headquartered in Boston, MA. | Director/Board Member | 2012-12-30 |
Training of Ryan Dietz
Indiana University Bloomington | Undergraduate Degree |
Boston University | Undergraduate Degree |
Suffolk University | Graduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Private companies | 3 |
---|---|
Immune Disease Institute, Inc.
Immune Disease Institute, Inc. Immune Disease Institute, Inc. provides biomedical research services. It engages in doing fundamental research to improve human health, harness inflammation, and strengthen immune defense. The company was founded on January 19, 1953 and is headquartered in Boston, MA. | |
Tio Bioventures
Tio Bioventures Investment ManagersFinance Tio Bioventures (Tio Bioventures) is a venture capital firm founded in 2019 by Tak Wah Mak and Shane Burgess. The firm is headquartered in New York. | Finance |
Treadwell Therapeutics, Inc.
Treadwell Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Treadwell Therapeutics, Inc. operates as a clinical-stage oncology firm. It develops small molecules designed to leverage world-class, innovative science in cancer biology and immune-oncology with pan-cancer potential, including hematological malignancies from the TIO Discovery development engine. The company was founded by Tak Wah Mak and Mark R. Bray in July 2019 and is headquartered in New York, NY. | Health Technology |
- Stock Market
- Insiders
- Ryan Dietz